DAX22.798 +1,3%ESt505.520 +0,5%Top 10 Crypto14,82 -0,6%Dow44.546 -0,4%Nas20.027 +0,4%Bitcoin91.794 +0,5%Euro1,0467 -0,1%Öl75,25 -0,1%Gold2.904 +0,2%

1 Aktie gratis Trading Krypto kaufen^* ETF-Sparplan

Hyloris Pharmaceuticals Aktie

NeuKaufen Verkaufen

5,14 EUR -0,22 EUR -4,10 %

17.02.2025

FSE

5,30 EUR +0,04 EUR +0,76 %

17.02.2025

EBR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

Bei einem anderen Broker handeln Smartphone

Smartphone

Marktkap.147,28 Mio. EUR

Div. Rendite0,00%

WKNA2P7Y0

ISINBE0974363955

Werbung

Hyloris Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

14.03.24GlobeNewswireHyloris Reports Full Year Results for 2023 & Provides Business Outlook

14.03.24GlobeNewswireCommunication at the request of the FSMA on the transactions with Qliniq

08.03.24GlobeNewswireHyloris to Report 2023 Full-Year Results on 14 March 2024

27.02.24GlobeNewswireHyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada

14.02.24GlobeNewswireHyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

30.01.24GlobeNewswireHyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

18.01.24GlobeNewswireHyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)

16.01.24GlobeNewswireOrphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

26.12.23GlobeNewswireHyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)

21.12.23GlobeNewswireHyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome

04.12.23GlobeNewswireHyloris announces US FDA approval for Podofilox Gel

24.10.23GlobeNewswireHyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada

18.10.23GlobeNewswireHyloris announces U.S. FDA Approval of Maxigesic® IV

06.09.23GlobeNewswireHyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook

22.06.23GlobeNewswireHyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM)

13.06.23GlobeNewswireHyloris shareholders approve all resolutions at the Annual General Meeting

08.06.23GlobeNewswireHyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region

02.05.23GlobeNewswireHyloris announces potential registration date for Maxigesic® IV in the US

28.04.23GlobeNewswireHyloris releases Annual Report 2022, including ESG objectives

18.04.23GlobeNewswireHyloris announces submission of Maxigesic® IV packaging data requested by the US FDA

15.03.23GlobeNewswireHyloris reports full year results for 2022 & provides business outlook

01.04.22GlobeNewswireHyloris Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering

31.03.22GlobeNewswireHyloris Launches Equity Offering by Means of a Private Placement Via an Accelerated Bookbuild Offering

16.03.22GlobeNewswireCorrecting -- Hyloris reports results for the full year 2021

16.03.22GlobeNewswireHyloris reports results for the full year 2021

Werbung

Hyloris Pharmaceuticals News

Hyloris Pharmaceuticals News: auf dieser Seite finden Sie alle Hyloris Pharmaceuticals News und Nachrichten zur Hyloris Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Hyloris Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Hyloris Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.